Skip to main content
CF PharmTech, Inc. logo

CF PharmTech, Inc. — Investor Relations & Filings

Ticker · 2652 HKEX Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2025-09-22 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2652

About CF PharmTech, Inc.

https://www.cfpharmtech.com

CF PharmTech, Inc. is a commercial-stage specialty pharmaceutical company specializing in the research, development, manufacturing, and commercialization of complex drug delivery systems, primarily focusing on inhalation technologies. The company develops treatments for major respiratory conditions, including asthma, Chronic Obstructive Pulmonary Disease (COPD), and allergic rhinitis. Its core product platforms encompass Inhalation Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), inhalation liquid preparations (nebulizers), and nasal sprays. The firm also leverages advanced formulation techniques, such as liposomes, to enhance drug efficacy and delivery.

Recent filings

Filing Released Lang Actions
PHIP (1st submission)
Regulatory Filings
2025-09-22 English
PHIP (1st submission)
Audit Report / Information Classification · 1% confidence The document is a 'PHIP' (Post-Hearing Information Proof) from the Hong Kong Stock Exchange (HKEX). A PHIP is a preliminary document published by a company intending to list on the exchange, serving as a draft prospectus. It contains sections typical of an IPO prospectus, such as 'Business', 'Financial Information', 'Risk Factors', and 'Accountants' Report'. Since it is a preliminary document related to a public offering and does not fit into the other specific categories like 10-K or IR, it is classified as a Regulatory Filing (RNS). FY 2018
2025-09-22 English
OC Announcement - Appointment
Capital/Financing Update Classification · 1% confidence The document is an announcement made pursuant to HKEX Listing Rule 12.01C detailing the appointment of overall coordinators (underwriting sponsors) for a proposed listing/public offering of CF PharmTech, Inc. It is not the full prospectus or listing document itself but an update on the company’s ongoing fundraising/listing process. Therefore this fits ‘Capital/Financing Update’ (CAP).
2025-06-11 English
Application Proof (1st submission)
Audit Report / Information Classification · 1% confidence The document is an 'Application Proof' for CF PharmTech, Inc., which is a standard term used in the Hong Kong Stock Exchange (HKEX) for a preliminary prospectus filed during an Initial Public Offering (IPO) process. The document lists various sections typical of a prospectus, such as 'Risk Factors', 'Business', 'Financial Information', and 'Accountants' Report'. Since the document is a landing page or index for an IPO prospectus, it falls under the category of a registration or offering document, which is best classified as 'POS' (as it relates to the issuance of shares) or more broadly as a regulatory filing. Given the specific options, 'POS' (Transaction in Own Shares/Capital Change) is often used for share-related filings, but since this is an IPO prospectus, 'RNS' (Regulatory Filings) is the most appropriate fallback for this type of offering document.
2025-06-11 English
Application Proof (1st submission)
Regulatory Filings Classification · 1% confidence The document is an “Application Proof” draft listing document (prospectus) for CF PharmTech’s Hong Kong IPO, detailing share offer structure, timetable, risk factors, financial appendices, etc. This is not an AGM presentation, annual report, earnings release, management change notice, or other specific category. Our taxonomy does not include a distinct “prospectus” slot, so this lengthy regulatory offering document falls under the general Regulatory Filings (RNS) fallback category.
2025-06-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.